Citigroup Maintains Buy on PTC Therapeutics, Raises Price Target to $109
Benzinga Newsdesk 3 hours ago
Analyst RatingsNewsPrice Target
Citigroup analyst Eric Joseph maintains PTC Therapeutics (NASDAQ:PTCT) with a Buy and raises the price target from $108 to $109.
Citigroup analyst Eric Joseph maintains PTC Therapeutics (NASDAQ:PTCT) with a Buy and raises the price target from $108 to $109.